

rejection of the claims of an application which had been pending for more than two years as of June 8, 1995, including any reference made to earlier filed applications under 35 U.S.C. §§120, 121, and 365(c). The present application is entitled to such treatment, which Applicants hereby request. A check for the required fee for a small entity, in the amount of \$375.00, is included herewith.

**In the Claims:**

Please amend the claims as follows:

D<sup>1</sup>

1. (Three times amended) A composition for use in the healing of wounds with no or at least reduced scarring as compared with healing by natural processes and for the treatment of fibrotic disorders, comprising TGFβ-3 [at least one non-fibrotic growth factor] with no fibrotic growth factor or with fibrotic growth factors or fragments thereof present in the composition in a lower proportion to TGFβ-3 [such non-fibrotic growth factor] than occurs naturally in the wounds or disorders in question, or with such fibrotic growth factors together with antibodies selected from the group which neutralize TGFβ-1, TGFβ-2 or PDGF [anti-fibrotic agents against them], all in a pharmaceutically acceptable carrier.

Please cancel claim 2 without prejudice.

D<sup>2</sup>

3. A composition according to claim 1, [wherein the non-fibrotic growth factor comprises] further comprising FGF.